Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated by Analysts at Scotiabank

Equities research analysts at Scotiabank began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The firm set a "sector outperform" rating and a $32.00 price target on the biotechnology company's stock. Scotiabank's target price would suggest a potential upside of 153.37% from the company's previous close.

A number of other brokerages have also recently commented on ARCT. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Wells Fargo & Company dropped their price objective on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Finally, Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $53.50.

Arcturus Therapeutics Trading Down 0.8%

Shares of ARCT stock traded down $0.10 during trading hours on Wednesday, reaching $12.63. The stock had a trading volume of 1,003,031 shares, compared to its average volume of 448,762. The stock's fifty day simple moving average is $11.30 and its 200 day simple moving average is $14.74. The firm has a market capitalization of $342.54 million, a PE ratio of -5.69 and a beta of 2.36. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. The firm had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of Arcturus Therapeutics during the first quarter valued at approximately $89,000. Acadian Asset Management LLC purchased a new stake in Arcturus Therapeutics during the 1st quarter valued at $701,000. Goldman Sachs Group Inc. increased its holdings in shares of Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company's stock worth $5,398,000 after purchasing an additional 42,636 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Arcturus Therapeutics in the first quarter worth $299,000. Finally, Millennium Management LLC bought a new position in shares of Arcturus Therapeutics during the first quarter valued at $4,892,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.